Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025
Carlsmed (Nasdaq: CARL) reported preliminary unaudited revenue of approximately $15.2 million for the fourth quarter of 2025, about +61% versus Q4 2024, and preliminary full year 2025 revenue of approximately $50.5 million, about +86% versus 2024.
Rhea-AI Summary
Carlsmed (Nasdaq: CARL) reported preliminary unaudited revenue of approximately $15.2 million for the fourth quarter of 2025, about +61% versus Q4 2024, and preliminary full year 2025 revenue of approximately $50.5 million, about +86% versus 2024. The company said it added 101 new surgeon users in 2025, a 61% increase in its surgeon user base, and launched aprevo cervical with early positive surgeon feedback. Results are preliminary, unaudited and subject to revision until the Company files its 2025 Annual Report on Form 10-K.
Positive
- Q4 2025 revenue of approximately $15.2M (+61% vs Q4 2024)
- Full year 2025 revenue of approximately $50.5M (+86% vs 2024)
- 101 new surgeon users added in 2025, a 61% increase in user base
- Commercial launch of aprevo cervical with encouraging early surgeon feedback
Negative
- Preliminary results are unaudited estimates and may be revised in the 2025 Form 10-K
Details
News Market Reaction – CARL
On Jan 12, the day this news came out, CARL closed 13.79% above the previous close.
Data tracked by StockTitan Argus for the Jan 12 session.
Key Figures
- Q4 2025 revenue
- $15.2M
- Preliminary, ~61% growth vs Q4 2024
- FY 2025 revenue
- $50.5M
- Preliminary, ~86% growth vs 2024
- New surgeon users 2025
- 101 surgeons
- Added to aprevo user base in 2025
- Surgeon base growth
- 61% increase
- Growth in total surgeon user base vs prior year
Historical Context
-
Published 2‑year lumbar data showing lower revision rates vs stock implants.
-
Announced upcoming J.P. Morgan Healthcare Conference presentation and investor meetings.
-
U.S. launch of aprevo cervical fusion platform and early clinical experience data.
-
Piper Sandler conference appearance and webcast details for investors.
-
Q3 2025 results with strong revenue growth and raised full‑year guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 10-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fourth quarter 2025 revenue of ~
Full Year 2025 revenue of ~
CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced preliminary and unaudited revenue for the fourth quarter and year ended December 31, 2025.
Preliminary Q4 & FY 2025 Revenue Results
- Fourth quarter 2025 revenue was approximately
$15.2 million , an approximate61% increase compared to the fourth quarter 2024. - Full year 2025 revenue was approximately
$50.5 million , an approximate86% increase compared to the full year 2024.
“Our fourth quarter commercial performance capped a transformational year for Carlsmed and underscores the power of aprevo®. This platform technology provides surgeons with greater procedural predictability and has the potential to meaningfully improve clinical outcomes in spine fusion and lower the total cost of care for the healthcare system. With growing enthusiasm for aprevo®, we added 101 new surgeon users in 2025, representing a
The preliminary unaudited revenue results described in this press release are estimates only and subject to revision and adjustment until the Company reports its full financial results for 2025 in its Annual Report on Form 10-K.
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements regarding Carlsmed’s preliminary estimated results for the fourth quarter and full year 2025 revenue, the potential of Carlsmed’s products, Carlsmed’s growth prospects, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in the Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
Caroline Corner, PhD
IR@Carlsmed.com
Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.